Neurobiological Models

Part of the The Depressive Illness Series book series (DISS, volume 2)


A neurobiological basis for at least some depressive disorders is suggested both by clinical features, including diurnal variation, delusions of guilt or illness, psychomotor change, and early morning awakening, as well as by the periodicity in the natural history and evidence for a genetic etiological component. Freud also held this view as indicated in his classic essay entitled “Mourning and Melancholia” where he commented: “Melancholia, whose definition fluctuates even in descriptive psychiatry, takes on various clinical forms, the grouping together of which into a single unity does not seem established with certainty; and some of these forms suggest somatic rather than psychogenic affectations” (Vol. XIV, p. 243). “What is probably a somatic factor, and one which cannot be explained psychogenically, makes itself visible in the regular amelioration in the condition that takes place towards evening …These considerations bring up the question …wether an impoverishment of ego-libido directly due to Toxins may not be able to produce certain forms of the disease.” (Vol. XIV, p. 253).


Depressive Disorder Depressed Patient Suicidal Behavior Growth Hormone Response Depressive Illness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Achor RWP, Harrison NO, Gifford RW Jr: Hypertension treated with rauwolfia serpentina (whole root) and with reserpine. JAMA 1955; 159: 841.Google Scholar
  2. 2.
    Asberg M, Bertilsson L, Thoreu P, Traskman L: CSF monoamine metabolites in depressive illness. In: Garattini S (Ed) Depressive Disorders. Stuttgart: FK Schattaner Verlag, 1978.Google Scholar
  3. 3.
    Banki CM, Arato M: Amine metabolites and neuroendocrine responses related to depression and suicide. J Aff Dis 1983; 5: 223–232.CrossRefGoogle Scholar
  4. 4.
    Birkmayer W, Riederer P: Biochemical postmortem findings in depressed patients. J Neur Trans 1975; 37: 95–109.CrossRefGoogle Scholar
  5. 5.
    Briley MS, Langer SZ, Raisman R, Sechter D, Zarifian E: 3H-Imipramine binding sites are decreased in platelets of untreated depressed patients. Science 1982; 209: 303–305.CrossRefGoogle Scholar
  6. 6.
    Brown RP, Kocsis JH, Frazer A: Serum melatonin in affective disorders. Am J Pyschiat 1985; 142: 811–816.Google Scholar
  7. 7.
    Brown RP, Mann JJ: Current theories of antidepressant action and the biochemical basis of depression. J Clin Psychiat Mono 1984; 2: 3–6.Google Scholar
  8. 8.
    Brown RP, Stoll PM, Stokes PE, Frances A, Sweeney JA, Kocsis JH, Mann JJ: Adrenocortical activity in depression: Effects of agitation, delusions, melancholia and other illness variables. Psychiat Res, 1988; 23: 167–178.CrossRefGoogle Scholar
  9. 9.
    Bunney WE Jr, Davis JM: Norepinephrine in depressive reactions: Review. Arch Gen Psychiat 1965; 13: 483–494.PubMedGoogle Scholar
  10. 10.
    Carlsson A, Rosengrew E, Bertler A, Nilsson J: Effect of reserpine on the metabolism of catecholamines. In: Garattini S, Ghetti V (Eds) Psychotropic Drugs. Amsterdam: Elsevier, 1957.Google Scholar
  11. 11.
    Carroll BJ, Curtis GC, Davies BM, Mendels J, Sugarman AA: Urinary free Cortisol excretion in depression. Psych Med 1976; 6: 43–50.CrossRefGoogle Scholar
  12. 12.
    Carroll BJ, Feinberg M, Greden JF, Tarika J, Albaia AA, Haskett RF, James NM, Krontol Z, Lohr N, Steiner M, de Vigne JP, Young E: A specific laboratory test for the diagnosis of melancholia. Arch Gen Psychiat 1981; 38: 15–22.PubMedGoogle Scholar
  13. 13.
    Charney DS, Menkes DB, Heninger GR: Receptor sensitivity and the mechanisms of action of antidepressant treatment. Arch Gen Psychiat 1981; 38: 1160–1180.PubMedGoogle Scholar
  14. 14.
    Checkley SA: Corticosteroid and growth hormone responses to methylamphetamine in depressive illness. Psych Med 1979; 9: 107–115.CrossRefGoogle Scholar
  15. 15.
    Checkley SA, Slade AP, Shur E: Growth hormone and other responses to Clonidine in patients with endogenous depression. Br J Psychiat 1981; 138: 51–55.CrossRefGoogle Scholar
  16. 16.
    Christensen NJ, Vestergard P, Sorensen T, Rafaelson OJ: Cerebrospinal fluid adrenaline in depressed patients. Acta Psychiatr Scand. 1980; 61: 178–182.PubMedCrossRefGoogle Scholar
  17. 17.
    Coccaro EF, Siever LJ, Klar H, Harber L, Owen K, Davis KL: 5-HT function and history of suicidal behavior. Abstracts New Research American Psychiatric Association 140th Annual Meeting May 1987: Chicago, p. 105.Google Scholar
  18. 18.
    Coppen A, Prange AJ Jr, Whybrow PC, Noguera R: Abnormalities of indoleamines in affective disorders. Arch Gen Psychiat 1972; 26: 474–478.PubMedGoogle Scholar
  19. 19.
    Costain DW, Green AR, Graham-Smith DG: Enhanced 5-hydroxytryptamine—mediated behavioral responses in rats following repeated electroconvulsive shock: Relevance to the mechanism of the antidepressive effect of electroconvulsive therapy. Psychopharm 1979; 61: 167–170.CrossRefGoogle Scholar
  20. 20.
    Crane GE: Iproniazid (marsilid) Phosphate, a therapeutical agent for mental disorders and debilitating diseases. Psychiat Res Rep Am Psychiat Ass 1957; 8: 142Google Scholar
  21. 21.
    De Meo M, McBride PA, Mann JJ, Keilp J: Fenfluramine challenge in major depression. New Research Abstract p 91. Am Psychiat Ass Meeting, May 1988, Canada.Google Scholar
  22. 22.
    DeMet EM, Halaris AE, Gwirtsman HE, Reno RM, Becker PI: Effects of desipramine on diurnal rhythms of plasma 3-methoxy-4-hydroxyphenyl- glycol (MHPG) in depressed patients. Psychopharm Bull 1982; 18: 221–223.Google Scholar
  23. 23.
    DeMontigny C, Cournoyer G, Morissette R, Langlois R, Caiilé A: Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Arch Gen Psychiat 1983; 40: 1327–34.Google Scholar
  24. 24.
    Deneker SJ, Haggendal J, Malm U: Noradrenaline content of cerebrospinal fluid in mental diseases. Lancet 1966; 2: 754.CrossRefGoogle Scholar
  25. 25.
    Doran AR, Rubinow DR, Roy A, Pickar D: CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients. Arch Gen Psychiat 1986; 43: 365–369.PubMedGoogle Scholar
  26. 26.
    Ferrier IN, McKeith IG, Cross AJ, Perry EK, Candy JM, Perry RH: Postmortem neurochemical studies in depression. In: Mann JJ, and Stanley M (Eds) Psychobiology of Suicidal Behavior. Annals New York Academy of Sciences, Vol 487, 128–142, 1986.Google Scholar
  27. 27.
    Frazer A, Brown R: Melatonin: A link between the environment and behavior. Integ Psychiat 1987; 5: 3–26.Google Scholar
  28. 28.
    Frazer A, Brown RP, Kocsis JH, Caroff S, Amsterdam J, Winokur A, Sweeney J, Stokes P: Patterns of melatonin rhythms in depression. J Neurotrans 1986; 21: 269–290.Google Scholar
  29. 29.
    Frazer A, Pandey GN, Mendels J: Metabolism and tryptophan in depressive disease. Arch Gen Psychiat 1973; 29: 528–535.PubMedGoogle Scholar
  30. 30.
    Freud S:Mourning’and melancholia. In: The Standard Edition of the Complete Psychological Works of Sigmund Freud, Vol. XIV. London: Hogarth Press, 1957.Google Scholar
  31. 31.
    Garcia-Sevilla JA, Zis AP, Hollingsworth PJ, Greden JF, Smith CB: Platelet alpha2-adrenergic receptors in major depressive disorders. Arch Gen Psychiat 1981; 38: 1327–1333.PubMedGoogle Scholar
  32. 32.
    Giles DE, Roffwarg AP, Schlessen MA, Rush AJ: Which endogenous depressive disorders related to REM latency reductions? Biol Psychiat 1986; 21: 473–482.PubMedCrossRefGoogle Scholar
  33. 33.
    Gold PW, Loriaux L, Roy A, Kling MA, Calabrese JR, Kellner CH, Nieman LK, Post RM, Pickar D, Gallucci W: Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing’s disease: Pathophysiologic and diagnostic implications. N Engl J Med 1986; 314: 1329–35.PubMedCrossRefGoogle Scholar
  34. 34.
    Goodlet F, Mireylees SE, Sugrue MF Effects of mianserin, a new antidepressant, on the in vitro and in vivo uptake of monoamines. Br] Pharmacol 1977; 61: 307–313.Google Scholar
  35. 35.
    Granata AR, Numao Y, Kumada M, Ries DJ: AI 21 noradrenergic neurons tonically inhibit sympathoexcitatory neurons of CI area in rat brainstem. Brain Res 1986; 377: 127–146.PubMedCrossRefGoogle Scholar
  36. 36.
    Halaris AE Evidence in support of a role of dopamine in affective illness. Psychopharm Bull 1982; 18: 31–34.Google Scholar
  37. 37.
    Harris TH Depression induced by rauwolfia compounds. Am J Psychiat 1957; 113: 950.PubMedGoogle Scholar
  38. 38.
    Hetlinger GR, Charney DS, Sternberg DE: Serotonergic function in depression. Arch Gen Psychiat 1984; 41: 398–402.Google Scholar
  39. 39.
    Janowsky DS, El-Yousef MK, Davis JM: Cholinergic-adrenergic hypothesis and mania and depression. Lancet 1972; ii: 632–635.CrossRefGoogle Scholar
  40. 40.
    Jones D, Kelwala S, Bell J, Dube S, Jackson E, Sitaram N: Cholinergic REM sleep induction response correlation with endogenous major depressive subtype. Psychiat Res 1985; 24: 99–110.CrossRefGoogle Scholar
  41. 41.
    Kaplan RD, Mann JJ: Altered platelet serotonin uptake in schizophrenia and melancholia. Life Sci 1982; 31: 583–588.PubMedCrossRefGoogle Scholar
  42. 42.
    Koslow S, Maas J, Bowden C, Davis J, Hamin I, Javaid J: Cerebrospinal fluid and urinary biogenic amines and metabolites in depression, mania, and healthy controls. A univariate analysis. Arch Gen Psychiat 1983; 40: 999–1010.PubMedGoogle Scholar
  43. 43.
    Krishnan KRR, Manepall AN, Ritchie JC, Rayersam K, Melville ML, Daughtry G, Thorner MD, Rivier JE, Nemeroff CB, Carroll BJ: Growth hormone-releasing factor stimulation in depression. Am J Psychiat 1988; 145: 90–92.PubMedGoogle Scholar
  44. 44.
    Kruk ZI, Pycock C: Neurotransmitters and Drugs, 2nd ed. Baltimore: University Park Press, 1983.Google Scholar
  45. 45.
    Langer G, Heinze G, Reim B, Matussek N: Reduced growth hormone responses to amphetamine in endogenous depressive patients: Studies in normal “reactive” and “endogenous” depressive, schizophrenic and chronic alcoholic subjects. Arch Gen Psychiat 1976, 33: 1471–1475.PubMedGoogle Scholar
  46. 46.
    Lemieux G, Davignon A, Genest J: Depressive states during rauwolfia therapy for arterial hypertension: A report of 30 cases. Can Med Ass J 1956; 74: 522.PubMedGoogle Scholar
  47. 47.
    Lewy AJ, Nurnberger JI, Wehr TA et al: Supersensitivity to light: Possible trait marker for manic-depressive illness. Am J Psychiat 1985; 142: 725–727.PubMedGoogle Scholar
  48. 48.
    Lingjaerde O: Tetrabenazine (nitoman) in the treatment of psychoses. Acta Psychiatrica Scand 1963; 39: 1 (suppl. 170).Google Scholar
  49. 49.
    Linoilla M, Karoum F, Potter WZ: High correlation of norepinephrine and its major metabolite excretion rates. Arch Gen Psychiat 1982; 39: 521–523.Google Scholar
  50. 50.
    Loosen PT, Prange AJ Jr: Thyrotropin releasing hormone (TRH): A useful tool for neuroendocrine investigation. Psychoneuroendocrin 1980; 5: 63–80.CrossRefGoogle Scholar
  51. 51.
    Mann JJ: Altered platelet monoamine oxidase activity in affective disorders. Psychol Med 1979; 9: 729–736.PubMedCrossRefGoogle Scholar
  52. 52.
    Mann JJ, Arango V CNS adrenergic receptors and beta blockade. In: Garlin R (Ed) A Quarter Century of Beta Blockade. Minneapolis: McGraw-Hill, 1988.Google Scholar
  53. 53.
    Mann JJ: Brown RP, Halper JP, Sweeney JA, Kocsis JH, Stokes PE, Bilezikian JP: Reduced sensitivity of lymphocyte beta-adrenergic receptors in patients with endogenous depression and psychomotor agitation. N Engl J Med 1985; 313: 715–720.PubMedCrossRefGoogle Scholar
  54. 54.
    Mann JJ, Halper JP, Sweeney JA, DeMeo M, Peters A, Wilner PJ, Kocsis JH, Brown RP In: Dahlstrom A, Belmaker R (Eds) Proceedings of the 6th International Catecholamine Symposium. New York: Alan Liss, 1987.Google Scholar
  55. 55.
    Mann JJ Stanley M: (Eds.): Psychobiology of suicidal behavior. Ann N Y Acad Sci 1986; 487, 1–357.Google Scholar
  56. 56.
    Mann JJ Stanley M, McBride PA, McEwen BS: Increased serotonin2 and betaadrenergic binding in frontal cortex of suicide victims. Arch Gen Psychiat 1986; 43: 954–959.PubMedGoogle Scholar
  57. 57.
    Meitzer HY: The serotonin hypothesis of depression. Abstracts, 25th Annual Meeting, American College of Neurospychopharmacology, December Washington DC, 1986, p 47.Google Scholar
  58. 58.
    Meitzer HY, Perline R, Tricou BJ, Lowry M, Robertson A: Effect of 5-hydroxytryptophan on serum Cortisol levels in major affective disorders. Arch Gen Psychiat 1984; 41: 379–387.Google Scholar
  59. 59.
    Meitzer HY, Nash JF, Ohmori T: Neuroendocrine and biochemical studies of serotonin and dopamine in depression and suicide. Abstract presented at The International Conference on New Directions in Affective Disorders (S60), 1987, Jerusalem, Israel.Google Scholar
  60. 60.
    Muller JC, Pryer WW, Gibbons JE, Orgain ES: Depression and anxiety occurring during rauwolfia therapy. JAMA 1955; 159: 836.Google Scholar
  61. 61.
    Ninan PT, van Kämmen DP, Scheinin M et al: CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. Am J Psychiat 1984; 141: 566–569.PubMedGoogle Scholar
  62. 62.
    Peroutka, SJ, Snyder SH: Chronic antidepressant treatment decreases spiroperidol-labelled serotonin receptor binding. Science 1980; 210: 88–90.PubMedCrossRefGoogle Scholar
  63. 63.
    Perris: A study of bipolar (manic-depressive) and unipolar recurrent depressive psychosis. VIII: Clinical-electroencephalographic investigation Acta Psychiatrica Scand 1966; Suppl. 1994: 118–152.Google Scholar
  64. 64.
    Post RM, Gordon EK, Goodwin FK et al: Central norepinephrine metabolism in affective illness. Sci 1973; 179: 1002–1003.CrossRefGoogle Scholar
  65. 65.
    Potter WZ, Ross RJ, Zavadol AP: NE in affective disorders: Classified biochemical approaches. In: Lake CR, Zeigler MG (Eds) The Catecholamine in Pyschiatry and Neurologic Disorders. Stonehame MT: Butterworth, 1985.Google Scholar
  66. 66.
    Potter WZ, Calil HM, Zavadol AP, Jusko WJ, Sutfiut, Rapaport JL, Goodwin FK: Steady-state concentration of hydroxylated metabolites of tricyclic antidepressants in patients: Relationship to clinical effect. Psychopharm Bull 1980; 16: 32–34.Google Scholar
  67. 67.
    Randrup A, Munkvad I, Fog R: Mania, depression, and brain dopamine: Overview. Psychopharm Bull 1982; 18: 35–36.Google Scholar
  68. 68.
    Reynolds CF, Kupfer DJ: Sleep research in affective disorders: State of the art circa 1987. Sleep 1987; 10: 199–215.PubMedGoogle Scholar
  69. 69.
    Risch SC, Janowsky DS, Judd LL, Huey LY: Elevated plasma beta-endorphin concentrations in depression and cholinergic supersensitive release mechanisms. Psychopharm Bull 1982; 18: 211–214.Google Scholar
  70. 70.
    Roy A, Everett D, Pickar D, Paul SM: Platelet tritiated imipramine binding and serotonin uptake in depressed patients and controls: Relationship to plasma Cortisol levels before and after dexamethasone. Arch Gen Psychiat 1987; 44: 320–327.PubMedGoogle Scholar
  71. 71.
    Rubin RT, Poland RE, Lesser IM, Winston RA, Blodgett ALN: Neuroendocrine aspects of primary endogenous depression: Cortisol secretory dynamics in patients and matched controls. Arch Gen Psychiat 1987; 44: 328–336.PubMedGoogle Scholar
  72. 72.
    Rudorfer MV, Ross RJ, Linoilla M, Sherer MA, Potter WZ: Exaggerated orthostatic responsivity of plasma norepinephrine in depression. Arch Gen Psychiat 1985; 42: 1186–1192.PubMedGoogle Scholar
  73. 73.
    Sachar EJ, Hellman L, Fukushima DK, Gallagher TF Cortisol production in depressive illness: A clinical and biochemical clarification. Arch Gen Psychiat 1970; 23: 289–298.PubMedGoogle Scholar
  74. 74.
    Schatzberg AF, Orsulak PJ, Rosenbaum AH, Toshihiko M, Kruger ER, Cole JO, Schildkraut JJ: Toward a biochemical classification of depressive disorders V: Heterogeneity of unipolar depressions. Am J Psychiat 1982; 139: 471–475.PubMedGoogle Scholar
  75. 75.
    Schildkraut JJ: The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiat 1965; 122: 509–522.PubMedGoogle Scholar
  76. 76.
    Schildkraut JJ, Orsulak PJ, Schatzberg AF, Gudeman JE, Cole JO, Rohde WA, La Brie RA: Toward a biochemical classification of depressive disorders, I: Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depression. Arch Gen Psychiat 1978; 35: 1427–1433.PubMedGoogle Scholar
  77. 77.
    Shaw DM, Kellman AMP, Mottram R: Brain Sciences in Psychiatry. London: Butterworth Scientific, 1982.Google Scholar
  78. 77.
    Shaw DM, Kellman AMP, Mottram R: Brain Sciences in Psychiatry. London: Butterworth Scientific, 1982.Google Scholar
  79. 79.
    Shopsin B, Friedman E, Gershon S: Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiat 1974; 33: 811–819.Google Scholar
  80. 80.
    Shopsin B, Green AR, Deakin JFW: Brain norepinephrine depletion prevents ECS-induced enhancement of serotonin- and dopamine-mediated behavior. Nature 1980; 285: 232–233.CrossRefGoogle Scholar
  81. 81.
    Siever LJ, Davis KL: Overview: Toward a dysregulation hypothesis of depression. Am J Psychiat 1985; 142: 1017–1031.PubMedGoogle Scholar
  82. 82.
    Siever LJ, Murphy DL, Slater S, de la Vega E, Lipper S: Plasma prolactin changes following fenfluramine in depressed patients compared to controls: An evaluation of central serotonergic responsivity in depression. Life Sci 1984; 34: 1029–1039.PubMedCrossRefGoogle Scholar
  83. 83.
    Siever LJ, Uhde TW, Jimerson DC, Lake CR, Silberman ER, Post RM, Murphy DL: Differential inhibitory noradrenergic responses to clonidine in 25 depressed patients and 25 normal control subjects. Am] Psychiat 1984; 141: 733–741.Google Scholar
  84. 84.
    Sitaram N, Gillin JC: Development and use of pharmacological probes of the CMS in man: Evidence of cholinergic abnormality in primary affective illness. Biol Psychiat 1980; 25: 925–955.Google Scholar
  85. 85.
    Snyder SH: Drug and neurotransmitter receptors in the brain. Science 1984; 224: 22–31.PubMedCrossRefGoogle Scholar
  86. 86.
    Stanley M, Mann JJ: Increased serotonin2 binding sites in frontal cortex of suicide victims. Lancet 1983; 1: 214–216.PubMedCrossRefGoogle Scholar
  87. 87.
    Stanley M, Mann JJ, Gershon S: Alterations in pre and postsynaptic serotonergic neurons in suicide victims. Psychopharm Bull 1983; 19: 684–687.Google Scholar
  88. 88.
    Stanley M, Virgilio J, Gershon S: Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science 1982; 216: 1337–1339.PubMedCrossRefGoogle Scholar
  89. 89.
    Stokes PE, Maas JW, Davis JM, Koslow SH, Caspar RC, Stoll PM: Biogenic amine and metabolite levels in depressed patients with high versus normal hypothalamic-pituitary-adrenocortical activity. Am J Psychiat 1987; 144: 868–872.PubMedGoogle Scholar
  90. 90.
    Stone EA: Problems with current catecholamine hypotheses of antidepressant agents: Speculations leading to a new hypothesis. Behav Brain Sci 1983; 6: 535–577.CrossRefGoogle Scholar
  91. 91.
    Sulser F: Update of neuroreceptor mechanisms and their implication for the pharmacotherapy of affective disorders. J Clin Psychiatry 1986; 47: 10 (suppl).Google Scholar
  92. 92.
    Swann AC, Koslow SH, Katz MM, Maas JW, Javaid J, Secunda SK, Robins E: Lithium carbonate treatment of mania. Cerebrospinal fluid and urinary monoamine metabolites and treatment outcome. Arch Gen Psychiat 1987; 44: 345–354.PubMedGoogle Scholar
  93. 93.
    Sweeney DR, Leckman JF, Maas JW, Hartox S, Heninger GR: Plasma free and conjugated MHPG in psychiatric patients. A pilot study. Arch Gen Psychiat 1980; 37: 1100–1103.PubMedGoogle Scholar
  94. 94.
    Traskman L, Asberg M, Bertilsson L et ah Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiat 1981; 38: 631–636.PubMedGoogle Scholar
  95. 95.
    Tuomisto J, Tukiainen E: Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients. Nature 1976; 262: 596–598.PubMedCrossRefGoogle Scholar
  96. 96.
    Vogel GW, Vogel F, McAbee RS, Thurmond AJ: Improvement of depression by REM sleep deprivation. Arch Gen Psychiat 1980; 37: 247–253.PubMedGoogle Scholar
  97. 97.
    Wehr TA: Biological rhythms and manic-depressive illness. In: Post RM, Ballenes JC (Eds) Neurobiology of Mood Disorders. Baltimore: Williams and Wilkins, 1984.Google Scholar
  98. 98.
    Wilner PJ, Brown RP, Sweeney JA, Halper JP, Tierney H, Mann JJ: Blunted orthostatic response in major depressives. New Research Abstracts, 140th Annual Meeting American Psychiatric Association, Chicago, 1987, p. 38.Google Scholar
  99. 99.
    Zeller EA, Barsky J: In vivo inhibition of liver and brain monoamine oxidase by l-isonicotinyl-2isopropylhydrazine. Proc Soc Exp Biol Med 1952; 81: 459.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  1. 1.Laboratory of Psychopharmacology, Department of PsychiatryCornell University Medical CollegeNew YorkUSA

Personalised recommendations